Eli Lilly Reports the P-II (SYNERGY-NASH) Study Data of Tirzepatide for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Shots:
- The 52wks. P-II (SYNERGY-NASH) trial assessed tirzepatide's (5mg, 10mg, & 15mg, SC, QW) safety & efficacy vs PBO in biopsy-confirmed MASH adults (n=190) with stage 2/3 fibrosis
- Efficacy estimand, featured at EASL 2024 & published in the NEJM, depicted MASH resolution without worsening fibrosis in 51.8%, 62.8% & 73.3% vs 13.2% & improved fibrosis (≥1-stage) without worsening MASH in 59.1%, 53.3% & 54.2% vs 32.8% of them along with changes in body wt., liver injury blood markers, liver fat biomarkers, inflammation & fibrosis
- Treatment-regimen estimand showed MASH resolution without worsening fibrosis in 43.6%, 55.5% & 62.4% vs 9.8% & reduction in fibrosis (>1 stage) without worsening MASH in 54.9%, 51.3% & 51.0% vs 29.7% of patients
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports the P-III (SURMOUNT-OSA) Study Data of Tirzepatide in Patients with Obstructive Sleep Apnea (OSA) and Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
